Literature DB >> 21996278

Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorphism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse.

Hans Jörgen Grabe1, Christian Schwahn, Jessie Mahler, Katja Appel, Andrea Schulz, Carsten Spitzer, Kristin Fenske, Sven Barnow, Harald Jürgen Freyberger, Alexander Teumer, Astrid Petersmann, Reiner Biffar, Dieter Rosskopf, Ulrich John, Henry Völzke.   

Abstract

BACKGROUND: Based on biological interactions between the serotonergic system and the brain-derived neurotrophic factor (BDNF), BDNF is a plausible candidate for a gene-gene-environment interaction moderating the interaction between the s/l- promoter polymorphism of the serotonin transporter (5-HTTLPR) and childhood abuse. We tested the hypothesis of a three-way interaction with respect to depressive symptoms.
METHODS: 2035 Caucasian subjects from the Study of Health in Pomerania (German general population) completed the Beck Depression Inventory (BDI-II) and the Childhood Trauma Questionnaire. All subjects were genotyped for the BDNF Val66Met (rs6265) and the s/l 5-HTTLPR polymorphisms.
RESULTS: Tobit regression analyses revealed a three-way-interaction between the three genotypes of 5-HTTLPR and the BDNF genotypes and overall childhood abuse for the BDI-II score (p=0.02). Emotional abuse carried the main effect of the interaction (p=0.008). The s/s genotype of the 5-HTTLPR exerted its negative impact on mental health after childhood abuse only in the presence of the BDNF Val/Val genotype but not in the presence of the BDNF Met allele. In contrast, the l allele of the 5-HTTLPR also emerged as a genetic risk factor for depression in carriers of one or two Met alleles.
CONCLUSIONS: Our results point to a gene-gene-environment interaction that relevantly impacts on the role of the s/s genotype of the 5-HTTLPR in childhood abuse: Depending on the BDNF background (Val/Val versus Met allele) the s/s genotype showed either protective or risk properties with regard to depressive symptoms.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996278     DOI: 10.1016/j.pnpbp.2011.09.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  28 in total

1.  Neurotrophic paths in the treatment of depression.

Authors:  Shawn Hayley; Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2013-09       Impact factor: 6.186

2.  Genetic susceptibility to family environment: BDNF Val66met and 5-HTTLPR influence depressive symptoms.

Authors:  Elizabeth D Dalton; Constance L Hammen; Jake M Najman; Patricia A Brennan
Journal:  J Fam Psychol       Date:  2014-10-27

3.  Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia.

Authors:  Yin Ting Cheung; Raja B Khan; Wei Liu; Tara M Brinkman; Michelle N Edelmann; Wilburn E Reddick; Deqing Pei; Angela Panoskaltsis-Mortari; Deokumar Srivastava; Cheng Cheng; Leslie L Robison; Melissa M Hudson; Ching-Hon Pui; Kevin R Krull
Journal:  JAMA Oncol       Date:  2018-07-12       Impact factor: 31.777

Review 4.  Early experience and brain development.

Authors:  Johanna Bick; Charles A Nelson
Journal:  Wiley Interdiscip Rev Cogn Sci       Date:  2016-12-01

5.  The risk for major depression conferred by childhood maltreatment is multiplied by BDNF and SERT genetic vulnerability: a replication study.

Authors:  Blanca Gutiérrez; Juan Á Bellón; Margarita Rivera; Esther Molina; Michael King; Louise Marston; Francisco Torres-González; Berta Moreno-Küstner; Patricia Moreno-Peral; Emma Motrico; Carmen Montón-Franco; María J GildeGómez-Barragán; Marta Sánchez-Celaya; Miguel Á Díaz-Barreiros; Catalina Vicens; Juan de Dios Luna; Irwin Nazareth; Jorge Cervilla
Journal:  J Psychiatry Neurosci       Date:  2015-05       Impact factor: 6.186

Review 6.  RDoC and translational perspectives on the genetics of trauma-related psychiatric disorders.

Authors:  Janitza L Montalvo-Ortiz; Joel Gelernter; James Hudziak; Joan Kaufman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2015-11-22       Impact factor: 3.568

7.  Influence of 5-HTT variation, childhood trauma and self-efficacy on anxiety traits: a gene-environment-coping interaction study.

Authors:  Miriam A Schiele; Christiane Ziegler; Karoline Holitschke; Christoph Schartner; Brigitte Schmidt; Heike Weber; Andreas Reif; Marcel Romanos; Paul Pauli; Peter Zwanzger; Jürgen Deckert; Katharina Domschke
Journal:  J Neural Transm (Vienna)       Date:  2016-05-04       Impact factor: 3.575

8.  Early life stress predicts negative urgency through brooding, depending on 5-HTTLPR genotype: A pilot study with 6-month follow-up examining suicide ideation.

Authors:  Jorge Valderrama; Regina Miranda
Journal:  Psychiatry Res       Date:  2017-09-01       Impact factor: 3.222

9.  Genome-wide gene-environment interaction in depression: A systematic evaluation of candidate genes: The childhood trauma working-group of PGC-MDD.

Authors:  Sandra Van der Auwera; Wouter J Peyrot; Yuri Milaneschi; Johannes Hertel; Bernhard Baune; Gerome Breen; Enda Byrne; Erin C Dunn; Helen Fisher; Georg Homuth; Douglas Levinson; Cathryn Lewis; Natalie Mills; Niamh Mullins; Matthias Nauck; Giorgio Pistis; Martin Preisig; Marcella Rietschel; Stephan Ripke; Patrick Sullivan; Alexander Teumer; Henry Völzke; Dorret I Boomsma; Naomi R Wray; Brenda Penninx; Hans Grabe
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-11-21       Impact factor: 3.568

10.  Personality-related factors as predictors of help-seeking for depression: a population-based study applying the Behavioral Model of Health Services Use.

Authors:  Georg Schomerus; Katja Appel; Peter J Meffert; Melanie Luppa; Ronald M Andersen; Hans J Grabe; Sebastian E Baumeister
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-12-25       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.